Children as young as 9 months can now be immunized for the prevention of meningococcal disease.
Children as young as 9 months now can be immunized for the prevention of invasive meningococcal disease, according to FDA.
Menactra (Sanofi Pasteur; Swiftwater, Pennsylvania) tetravalent conjugate vaccine was first approved in 2005 to protect people aged 2 through 55 years against meningitis caused by Neisseria meningitidis serogroups A, C, Y and W-135. The bacteria invade the bloodstream and the meninges that surround the brain and spinal cord and can cause neurologic problems, coma, and even death.
Between 10% and 15% of patients who develop meningococcal disease die from the infection, and another 10% to 20% develop complications such as brain damage or loss of limbs and hearing.
FDA granted approval for Menactra in this age group after reviewing 4 clinical studies that evaluated the safety of Menactra for children as young as 9 months.
The most common adverse effects reported in children who received the Menactra vaccine were comparable to a control group that received other childhood vaccinations: tenderness at the injection site, fever, and general irritability. Serious adverse events recorded through 6-month follow-up occurred in less than 3% of the children.
Stress ulcer prophylaxis does not provide prevention of gastrointestinal bleeding in neonates
December 4th 2023In a poster abstract presented at the American Society of Health-System Pharmacists Midyear Clinical Meeting & Exhibition held in Anaheim, California, stress ulcer prophylaxis (SUP) did not appear to provide benefit for prevention of gastrointestinal bleeding and did not increase SUP-associated adverse effects.
Hematocrit levels in newborns: EPP vs DCC study reveals surprising findings
November 15th 2023A recent study in JAMA Network Open investigates the impact of extrauterine placental perfusion versus delayed cord clamping on hematocrit levels in newborns, shedding light on potential alternatives for optimizing infant outcomes during birth.
Preterm infant HRQOL: Long-term impacts and determinants
October 21st 2023A recent study was highlighted at the 2023 American Academy of Pediatrics National Conference & Exhibition that shed light on the long-term impact of very preterm birth on the health-related quality of life (HRQOL) of infants and identified key determinants.